Liposomal Bupivacaine Versus Standard Analgesia in Total Joint Arthroplasty (TJA)

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether liposomal bupivacaine is effective in the management of pain following total joint arthroplasty, as compared to standard of care analgesia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OhioHealth
• Treatments: Bupivacaine; Epinephrine; Fentanyl; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Morphine; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Ropivacaine

Criteria

Inclusion Criteria:

1. Clinical diagnosis of osteoarthritis

2. Elected to undergo primary TKA, THA, or TSA

Exclusion Criteria:

1. Age < 18 years

2. Pregnant or breastfeeding

3. Non-English speaking

4. Unable to give informed consent

5. Previous open hip, knee or shoulder surgery

6. Pre-determined patients discharging to ECF

7. Patients with allergies to bupivacaine

8. Patients currently taking opioid pain medication

9. Patients with contraindication to nerve blocks

10. Patients undergoing simultaneous bilateral joint replacement, as this would require >1 dose of liposomal bupivacaine (Exparel®) per patient for each surgical site

11. Patients with severe hepatic disease

12. Patients with chronic heart disease as defined as a decreased ejection fraction